
FDA panel backs Darzalex for early stage multiple myeloma
Expert advisers to the Food and Drug Administration on Tuesday backed Johnson & Johnson’s Darzalex for people with an asymptomatic form of multiple myeloma that often progresses into more severe blood cancer. Members of the Oncologic Drugs Advisory …